Akeso: China's Biotech Champion Takes off – and now Targets the US Market

Amid the ongoing debate over trade tariffs and geopolitical isolation, a Chinese biotech company is making international waves. Akeso Inc. , previously known mainly in its home country, has announced an ambitious attack on one of the world's most successful drugs: Keytruda from Merck. In a clinical study involving Chinese patients, Akeso's active substance Ivonescimab proved to be more effective than the billion-dollar blockbuster Keytruda – an immuno-oncology drug expected to generate over $30 billion in revenue worldwide in 2024. Akeso's...